|Dr. Todd C. Brady||Chief Exec. Officer, Pres and Director||660k||N/A||1972|
|Mr. Stephen J. Tulipano CPA, MBA||Chief Financial Officer and Treasurer||406.89k||N/A||1959|
|Dr. David J. Clark M.D., M.R.C.P., A.F.P.M.||Chief Medical Officer||461.53k||N/A||1965|
|Ms. Mary Taylor M.P.H.||Sr. VP of Regulatory Affairs||N/A||N/A||1959|
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Aldeyra Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.